Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Continued Access Protocol for Eligible US Subjects With Duchenne Muscular Dystrophy Who Previously Participated in an Approved Drisapersen Study

NCT01890798 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01890798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01890798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Continued Access Protocol for Eligible US Subjects With Duchenne Muscular Dystrophy Who Previously Participated in an Approved Drisapersen Study
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Withdrawn
Start date
January 31, 2014
Completion date
July 31, 2015
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

muscular dystrophies